Selank: Evidence, Safety, Dosing Questions, and Access

Selank is a synthetic tuftsin-analogue peptide studied mainly for anxiety-related conditions. Its evidence grade is A because at least two human randomized controlled trials are indexed in PubMed, but that grade describes study quantity and design—not proof that Selank works or is safe for everyone 1, 2, 3.

What it is

Selank is a synthetic peptide commonly described as TP-7 and as an analogue of tuftsin, a short immune-related peptide sequence discussed in the tuftsin-analogue literature 5. In patient searches, Selank is most often discussed for anxiety, stress, and nootropic uses, but the retrieved human studies focus most clearly on anxiety disorders; Selank is not FDA-approved for anxiety, stress, nootropic use, or any other indication in the U.S. 1, 2, 3.

Names to know: Selank, TP-7, and tuftsin analogue

The names can be confusing. Selank is the common name; TP-7 is another identifier; “tuftsin analogue” describes its relationship to tuftsin, the parent peptide family discussed in medicinal chemistry reviews 5. If you are comparing peptide articles, our deeper background pieces on what Selank is and N-acetyl Selank can help separate related names.

What Selank is commonly discussed for

In the retrieved PubMed-indexed human literature, Selank appears in studies of anxiety disorders, including generalized anxiety disorders and neurasthenia, and in a clinical comparison with phenazepam for anxiety disorders 1, 2, 3. That does not mean it is right for a given person, and it does not replace evaluation for anxiety, panic symptoms, depression, sleep problems, substance use, or medication interactions.

Mechanism of action

The honest answer is that Selank’s full mechanism in humans is not established. Selank is proposed to work through tuftsin-related peptide biology and nervous-system pathways, but proposed mechanisms are not the same as proven clinical effects 4, 5.

Tuftsin-analogue background

Tuftsin and its analogues are discussed as biologically active short peptides in medicinal chemistry literature 5. Selank is described within that tuftsin-analogue context, which gives researchers a reason to study nervous-system and immune-related effects, but it does not by itself prove a patient benefit 5.

Human mechanism research versus animal mechanism research

A human functional-connectomic study examined Selank and Semax effects, which means researchers looked at patterns of brain-network activity rather than measuring a standard treatment outcome 4. Animal research has also studied Selank in rat models, including ethanol-induced memory impairment with BDNF-related measures and morphine-withdrawal signs in rats 6, 7.

Why mechanism findings do not prove clinical benefit

A pathway can look promising and still fail to help patients in a controlled trial. That is why we separate mechanism research from clinical evidence: functional connectomics, BDNF measures, and animal behavior models are not the same as long-term, patient-centered outcomes 4, 6, 7.

Evidence

Selank receives evidence grade A on this page because the retrieved evidence set includes at least two PubMed-indexed human randomized controlled trials 1, 3. That grade is about the amount and design of indexed research, not a claim that Selank works, is safe for everyone, or has complete long-term data.

Why Selank is grade A by study design

The retrieved evidence includes a randomized controlled trial on Selank in generalized anxiety disorders and neurasthenia, and another randomized controlled trial on optimizing anxiety-disorder treatment with Selank 1, 3. A separate human clinical trial compared the anxiolytic effect and tolerability of Selank and phenazepam in anxiety disorders 2.

What the anxiety-disorder studies can and cannot show

The anxiety-disorder studies make Selank more evidence-grounded than many peptides that have only animal or cell data 1, 2, 3. Still, the retrieved records do not establish broad real-world effectiveness, long-term outcomes, or whether Selank is appropriate for people with complex psychiatric histories, sedative use, substance-use history, pregnancy, or multiple medications.

What is still unknown about long-term safety and real-world use

The available human studies include anxiety-disorder and tolerability-focused work, but the retrieved evidence set is not enough to rule out rare side effects, long-term risks, or interaction problems 1, 2, 3. Individual results vary in peptide research, and small or narrow study sets can miss problems that only appear with wider use.

What studies exist

This table is retrieved from PubMed and ClinicalTrials.gov rather than assembled by hand, so it shows what is indexed — including the absences. Last retrieved 2026-09-10.

Reported dosing ranges

The retrieved PubMed records confirm that Selank has been studied in human anxiety-disorder trials, but the source list provided for this article does not include extractable dosing ranges from those studies 1, 2, 3. Published study context is not personal dosing advice; dosing questions belong in a clinician evaluation.

Why published study dosing is not personal dosing advice

Even when a study reports a dose, that number belongs to that study’s route, population, design, and monitoring plan. It should not be turned into instructions for a reader, especially when psychiatric symptoms, sedatives, alcohol use, other medications, or substance-use history may change risk.

For more context on how research dosing should be read, see our article on Selank peptide dosing. The key point is simple: study dosing is a research detail, not a safe plan for self-use.

Legal status

Our regulatory log holds no confirmed federal action for Selank. That means we have not found one with a primary source — not that none exists.

This section is generated from a dated log of federal actions rather than written by hand, and it is re-checked daily against the Federal Register and FDA sources. Last checked 2026-09-10. See the full legal-status tracker for every compound we follow.

Safety

Selank safety data in the retrieved evidence set is limited. A human clinical trial compared the anxiolytic effect and tolerability of Selank and phenazepam in anxiety disorders, and the randomized anxiety-disorder studies add human experience, but those records do not settle rare, long-term, pregnancy, psychiatric, or interaction risks 1, 2, 3.

What human tolerability data exists

The clearest retrieved tolerability signal is that tolerability was part of a human comparison trial of Selank and phenazepam in anxiety disorders 2. That is useful, but it is not the same as a large safety database across many ages, conditions, medication combinations, and years of follow-up.

Why limited trials cannot rule out rare or long-term risks

Small or narrow clinical studies can miss uncommon events. The retrieved human studies are not enough to rule out rare allergic reactions, mood changes, sedation-like effects, worsening anxiety, withdrawal-like experiences, or problems when Selank is combined with psychiatric medications, sedatives, alcohol, or other peptides 1, 2, 3.

When to involve a licensed clinician

A licensed clinician should be involved when symptoms include panic attacks, severe anxiety, depression, suicidal thoughts, bipolar symptoms, psychosis, substance-use concerns, pregnancy, breastfeeding, or use of benzodiazepines, sleep medications, antidepressants, stimulants, opioids, or alcohol. Those risks are exactly why self-directed peptide use is not a substitute for care.

Interactions

No dedicated Selank drug-interaction studies are identified in the retrieved evidence list. That is not reassurance; it means interaction risk is incompletely characterized, especially for anxiety medications, sedatives, alcohol, psychiatric history, and other nervous-system-active substances.

Why anxiety medications, sedatives, and psychiatric history matter

The human Selank studies in this evidence set center on anxiety disorders and include comparison with phenazepam, a benzodiazepine-class anxiolytic used in some countries 2. Because anxiety symptoms and sedating medicines can overlap in real life, a clinician needs to review current medications, alcohol use, sleep aids, prior medication reactions, and psychiatric history before any peptide decision.

Why interaction evidence may be incomplete

Interaction studies are separate from efficacy studies. The fact that Selank appears in anxiety-disorder trials does not tell us how it behaves with antidepressants, benzodiazepines, stimulants, opioids, alcohol, antihistamines, sleep medicines, or other peptides in broad real-world use 1, 2, 3.

How to obtain it legally

For any peptide, the legitimate medical process starts with a clinician evaluation, a prescription only where clinically appropriate, and dispensing through a licensed pharmacy with follow-up. Selank is not offered by Chia; we provide clinician-reviewed care only for treatments listed in our live catalog, and compounded drugs are not FDA-approved.

What clinician evaluation should include

A good evaluation should cover the symptom being targeted, mental-health history, sleep, substance use, pregnancy or breastfeeding, allergies, current prescriptions, supplements, prior reactions to anxiety medicines, and what follow-up will look like. A prescription, when part of care, should come only after that review and is never guaranteed.

Why research-chemical vendors are not medical care

A research-chemical website does not evaluate your symptoms, screen for interactions, confirm that a peptide is appropriate, monitor adverse effects, or coordinate care with your other medicines. “Research use only” labeling also does not make a product suitable for human use.

What to ask about identity, purity, adverse-event reporting, and follow-up

• Who is evaluating whether the peptide fits your medical history?
• What pharmacy or facility prepares the product?
• How are identity, purity, potency, and sterility checked?
• Who receives and responds to adverse-event reports?
• What follow-up is planned if symptoms worsen or side effects appear?
• How will the clinician account for psychiatric medications, sedatives, alcohol, and other peptides?

If your goals are closer to treatments Chia does offer, such as clinician-reviewed longevity or metabolic care, our current catalog includes options like Sermorelin, NAD+, glutathione, and GLP-1-based weight care. That does not mean those treatments are substitutes for Selank; it means the safest path starts with matching the goal to an evaluated treatment.

How does Selank compare with Semax?

Selank and Semax are often discussed together, but they should be compared study by study, not by internet reputation. A human functional-connectomic study examined both Selank and Semax effects, while Selank’s retrieved clinical studies focus mainly on anxiety disorders 1, 3, 4.

Different research questions, different proposed uses

Selank is most directly represented in the retrieved clinical literature through anxiety-disorder studies 1, 2, 3. Semax is a separate peptide with its own evidence questions; if you are comparing them, start with our Semax evidence guide or the deeper Semax cognitive and neuroprotective peptide guide.

Why evidence should be compared study by study

A peptide can have more studies for one use and much less evidence for another. That is why we avoid saying one is “better” in general; better depends on the health goal, study quality, safety data, and clinician judgment.

Keep reading

Peptides

Selank Peptide Dosing: What Research Shows and What Patients Should Know

Peptides

N-Acetyl Selank Peptide: What It Is, What the Evidence Shows, and Safety Limits

Peptides

What Is Selank Peptide? Uses, Evidence, Safety, and FDA Status